U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C28H38NO4.Br
Molecular Weight 532.51
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUTROPIUM BROMIDE

SMILES

[Br-].CCCCOC1=CC=C(C[N@+]2(C)[C@H]3CC[C@@H]2C[C@@H](C3)OC(=O)[C@H](CO)C4=CC=CC=C4)C=C1

InChI

InChIKey=JABDOYKGZCPHPX-XSCYYCMVSA-M
InChI=1S/C28H38NO4.BrH/c1-3-4-16-32-25-14-10-21(11-15-25)19-29(2)23-12-13-24(29)18-26(17-23)33-28(31)27(20-30)22-8-6-5-7-9-22;/h5-11,14-15,23-24,26-27,30H,3-4,12-13,16-20H2,1-2H3;1H/q+1;/p-1/t23-,24+,26+,27-,29?;/m1./s1

HIDE SMILES / InChI

Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C28H37NO4
Molecular Weight 451.5977
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 4 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.mims.com/malaysia/drug/info/coliopan and http://www.genome.jp/dbget-bin/www_bget?D01491

Butropium Bromide is an anticholinergic and an antispasmodic. It is a Muscarinic receptor antagonist. The drug is used for remission of spasmodic pain in the following diseases: gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia). It is marketed in Japan under the brand name Coliopan.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Coliopan

Approved Use

Remission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia)

Launch Date

1974
Palliative
Coliopan

Approved Use

Remission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia)

Launch Date

1974
Palliative
Coliopan

Approved Use

Remission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia)

Launch Date

1974
Doses

Doses

DosePopulationAdverse events​
10 mg 3 times / day multiple, oral
Recommended
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: unknown
Food Status: UNKNOWN
Sources:
4 mg 1 times / day single, intravenous
Studied dose
Dose: 4 mg, 1 times / day
Route: intravenous
Route: single
Dose: 4 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: Palpitation, Increased thirst...
Other AEs:
Palpitation
Increased thirst
Urination difficulty (1 pt)
Sources:
AEs

AEs

AESignificanceDosePopulation
Increased thirst
4 mg 1 times / day single, intravenous
Studied dose
Dose: 4 mg, 1 times / day
Route: intravenous
Route: single
Dose: 4 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Palpitation
4 mg 1 times / day single, intravenous
Studied dose
Dose: 4 mg, 1 times / day
Route: intravenous
Route: single
Dose: 4 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Urination difficulty 1 pt
4 mg 1 times / day single, intravenous
Studied dose
Dose: 4 mg, 1 times / day
Route: intravenous
Route: single
Dose: 4 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Endoscopic manometry of the sphincter of Oddi in dogs. Pharmacological effects of anticholinergic and selective antimuscarinic agents.
1987-05
Sensation of aural fullness and its treatment with an autonomic nerve blocking agent.
1987
Effect of glucagon on gastric motility examined by the acetaminophen absorption method and the endoscopic procedure.
1985
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Can also be administered intramuscularly http://www.ncbi.nlm.nih.gov/pubmed/7182948
Capsules 5 mg:The usual adult dosage for oral use is 6 capsules (30 mg ofbutropium bromide) daily in three divided doses. Tablets 10 mg:The usual adult dosage for oral use is 3 tablets (30 mg ofbutropium bromide) daily in three divided doses. Granules 2 %:The usual adult dosage for oral use is 1.5 g (30 mg ofbutropium bromide) daily in three divided doses.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:43:27 GMT 2025
Edited
by admin
on Wed Apr 02 07:43:27 GMT 2025
Record UNII
R3K4503MV7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
COLIOPAN
Preferred Name English
BUTROPIUM BROMIDE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
8-(P-BUTOXYBENZYL)-3.ALPHA.-HYDROXY-1.ALPHA.H,5.ALPHA.H-TROPANIUM BROMIDE (-)-TROPATE
Common Name English
8-AZONIABICYCLO(3.2.1)OCTANE, 8-((4-BUTOXYPHENYL)METHYL)-3-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-8-METHYL-, BROMIDE, (3(S)-ENDO)-
Common Name English
BUTROPIUM BROMIDE [MART.]
Common Name English
BUTROPIUM BROMIDE [JAN]
Common Name English
BUTROPIUM BROMIDE [MI]
Common Name English
Butropium bromide [WHO-DD]
Common Name English
butropium bromide [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29704
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
Code System Code Type Description
SMS_ID
100000081568
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
EVMPD
SUB06037MIG
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
INN
3498
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
ChEMBL
CHEMBL2110820
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
EPA CompTox
DTXSID1022716
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
CHEBI
31327
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
FDA UNII
R3K4503MV7
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
ECHA (EC/EINECS)
249-375-4
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
MERCK INDEX
m2806
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY Merck Index
NCI_THESAURUS
C81548
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
MESH
C006846
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
CAS
29025-14-7
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY